Biomarkers of treatment response in patients with progressive multiple sclerosis treated with high‐dose pharmaceutical‐grade biotin (MD1003)

Biomarkers of treatment response in patients with progressive multiple sclerosis treated with high‐dose pharmaceutical‐grade biotin (MD1003)

Abstract Background High‐dose pharmaceutical‐grade biotin (MD1003) has positive effects on disability in progressive multiple sclerosis (PMS), but its mechanism of action remains unclear. The objective of our study was to quantify the effect of MD1003 in patients with PMS, using clinical response, p...

Full description

Bibliographic Details
Main Authors: Nicolas Collongues, Jens Kuhle, Charidimos Tsagkas, Julien Lamy, Nicolas Meyer, Christian Barro, Katrin Parmar, Michael Amann, Jens Wuerfel, Ludwig Kappos, Thibault Moreau, Jerome deSeze
Format: Article
Language:English
Published: Wiley 2021-02-01
Series:Brain and Behavior
Subjects:
brain volume
MD1003
multiple sclerosis
neurofilament light chain
progressive form
spinal cord volume
Online Access:https://doi.org/10.1002/brb3.1998

Internet

https://doi.org/10.1002/brb3.1998

Similar Items